Labcorp Introduces First-of-its-Kind Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries

Labcorp Introduces First-of-its-Kind Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries.

Labcorp, a global leader in innovative laboratory services, has introduced the nation's first test for glial fibrillary acidic protein (GFAP), a crucial blood-based biomarker for early detection of neurodegenerative diseases and neurological injuries.

GFAP test, the first of its kind available commercially nationwide, provides physicians with a more efficient means of assessing the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma, and injuries like traumatic brain injury (TBI).

It expands Labcorp's comprehensive neurology portfolio, which includes biomarker tests for neurofilament light chain (NfL), pTau181, pTau217, and beta amyloid 42/40.

The introduction of the GFAP biomarker test marks a significant milestone for Labcorp, extending leadership in the rapidly accelerating field of blood-based biomarkers for neurodegenerative diseases.

GFAP, typically found in the brain's support cells known as astrocytes, is released into the blood during neurodegenerative disease or injury, enabling assessment through a blood test. GFAP has been extensively studied as an early-stage indicator of neurological damage.

The company's commitment to providing physicians with cutting-edge technology to enhance patient care. The GFAP test utilizes highly sensitive immunoassay technology to measure GFAP levels from a simple blood draw, which can be performed in hospitals, physician's offices, or any of Labcorp's more than 2,000 patient service centers nationwide.

Source: https://www.labcorp.com/labcorp-announces-first-its-kind-test-early-indication-neurodegenerative-diseases-and-brain